Significant Product and Pipeline Approvals Strategy The following is a summary of the significant approvals received in 2019: Refer to “—Product and Pipeline Developments” for all of the developments in our marketed products and late-stage pipeline in 2019 and in early 2020. (a) The regulatory approval was obtained by Celgene prior to the completion of the Celgene transaction. Our principal strategy is to combine the resources, scale and capability of a pharmaceutical company with the speed and focus on innovation of the biotech industry. Our focus as a biopharmaceutical company is on discovering, developing and delivering transformational medicines for patients facing serious diseases in areas where we believe that we have an opportunity to make a meaningful difference: oncology (both solid tumors and hematology), immunology, cardiovascular and fibrosis. Our four strategic priorities as a combined company are to drive enterprise performance, maximize the value of our commercial portfolio, ensure the long-term sustainability of our pipeline through combined internal and external innovation and establish our new culture and embed our people strategy. Product Date Approval Revlimid December 2019 EC approval in combination with rituximab for the treatment of adult patients with previously treated FL (Grade 1-3a).  Revlimid and rituximab (R$^{2}$) is the first chemotherapy-free combination regimen approved for the patients with FL by the EC. Opdivo+Yervoy March 2019 Conversion of accelerated FDA approval to full FDA approval for  Opdivo+Yervoy for first line metastatic melanoma treatment based on longer follow-up data from CheckMate-067. January 2019 EC approval of  Opdivo plus low-dose  Yervoy for previously untreated patients with intermediate and poor-risk advanced RCC. Orencia April 2019 EC approval of two new strengths (50 mg and 87.5 mg) for subcutaneous administration, and a new indication for  Orencia  injection for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in pediatric patients 2 years of age and older. Sprycel February 2019 EC approval in both tablet and powder for oral suspension formulations, in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive ALL. Empliciti November 2019 Approved in Japan in combination with pomalidomide and dexamethasone for multiple myeloma following at least two prior therapies, including lenalidomide and proteasome inhibitor. August 2019 EC approval in combination with pomalidomide and dexamethasone for adult patients with RRMM who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on the last therapy. Inrebic (a) August 2019 FDA approval for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. Reblozyl (a) November 2019 FDA approval for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions. 33